Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Fecal microbiota transplant treats C. difficile in immunocompromised patients

A study in this month's issue of the American Journal of Gastroenterology examines fecal microbiota transplant for the treatment of Clostridium difficile infection in immunocompromised patients.

News image

Patients who are immunocompromised are at increased risk of Clostridium difficile infection (CDI), which has increased to epidemic proportions over the past decade.

Fecal microbiota transplantation (FMT) appears effective for the treatment of Clostridium difficile, although there is concern that immunocompromised patients may be at increased risk of having adverse events related to FMT.

Dr Colleen Kelly and colleagues from Rhode Island, USA describe the multicenter experience of FMT in immunocompromised patients.

A multicenter retrospective series was performed on the use of FMT in immunocompromised patients with Clostridium difficile that was recurrent, refractory, or severe.

The research team described rates of Clostridium difficile cure after FMT as well as adverse events experienced by immunocompromised patients after FMT.

79% were outpatients at the time of FMT
American Journal of Gastroenterology

A 32-item questionnaire soliciting demographic and pre- and post-FMT data was completed for 99 patients at 16 centers, of whom 80 were eligible for inclusion.

Outcomes included rates of Clostridium difficile cure after FMT, serious adverse events such as death or hospitalization within 12 weeks of FMT, infection within 12 weeks of FMT, and adverse events.

Cases included 75 adult and 5 pediatric patients treated with FMT for recurrent, refractory, and severe and/or overlap of recurrent/refractory and severe Clostridium difficile.
 
The team noted that in all, 79% were outpatients at the time of FMT.

The mean follow-up period between FMT and data collection was 11 months.

Reasons for immunocompromise included HIV/AIDS, solid organ transplant, oncologic condition, immunosuppressive therapy for inflammatory bowel disease, and other medical conditions/medications.

The research team found that the Clostridium difficile cure rate after a single FMT was 78%, with 62 patients suffering no recurrence at least 12 weeks post FMT.

The team identified 12 patients who underwent repeat FMT, of whom 8 had no further Clostridium difficile.

Thus, the overall cure rate was 89%.

The researchers found that 15% had any serious adverse event within 12 weeks post FMT, of which 10 were hospitalizations.

The team observed 2 deaths occurred within 12 weeks of FMT, one of which was the result of aspiration during sedation for FMT administered via colonoscopy, and the other was unrelated to FMT.

None suffered infections definitely related to FMT, but 2 patients developed unrelated infections and 5 had self-limited diarrheal illness in which no causal organism was identified.

The team found 1 patient had a superficial mucosal tear caused by the colonoscopy performed for the FMT, and 3 patients reported mild, self-limited abdominal discomfort post FMT.

About 14% of patients experienced disease flare post FMT.

The research team noted 3 ulcerative colitis patients that underwent colectomy related to course of UC >100 days after FMT.

Dr Kelly's team concludes, "This series demonstrates the effective use of FMT for Clostridium difficile in immunocompromized patients with few serious adverse events or related adverse events."

"Importantly, there were no related infectious complications in these high-risk patients."

Am J Gastroenterol 2014; 109:1065–1071
11 July 2014

Go to top of page Email this page Email this page to a colleague

 07 March 2015

Advanced search
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
Risk of anastomotic leak after colectomy
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patients’ colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us